Monospecific and bispecific human monoclonal antibodies targeting insulin-like growth factor ii (igf-ii)
AssigneeThe United States of America, as represented by the Secretary, Department of Health and Human
InventorsDimiter S. Dimitrov, Weizao Chen, Yang Feng
Life of this patent
Estimating the term…
Abstract
Monoclonal antibodies (mAbs), antigen binding fragments and engineered antibody domains (eAds) that specifically bind IGF-II are disclosed herein. In some embodiments, these mAbs and eAds are included in a bispecific mAb. In some embodiments, the bispecific antibody specifically binds two different epitopes of IGF-II. Methods of using these mAbs, antigen binding fragments, and eAds, bispecific antibodies, and nucleic acids encoding these mAbs, antigen binding fragments, and eAds, bispecific antibodies are also disclosed.
Claims49
(canceled)
An isolated monoclonal antibody, comprising a heavy chain variable domain comprising a heavy chain complementarity determining region (H-CDR)1, H-CDR2 and H-CDR3 and a light chain variable domain comprising a light chain complementarity determining region (L-CDR)1, LCDR2 and L-CDR3, wherein the H-CDR1 comprises the amino acid sequence set forth as amino acids 26 to 33 of the amino acid sequence set forth as SEQ ID NO:
- 1, the H-CDR2 comprises amino acids 51 to 58 of the amino acid sequence set forth as SEQ ID NO:
- 1, and the H-CDR3 comprises amino acids 97 to 109 of the amino acid sequence set forth as SEQ ID NO:
- 1, and wherein the L-CDR1 comprises the amino acid sequence set forth as amino acids 27 to 32 of the amino acid sequence set forth as SEQ ID NO:
- 2, the L-CDR2 comprises amino acids 50 to 52 of the amino acid sequence set forth as SEQ ID NO:
- 2, and the L-CDR3 comprises amino acids 89 to 98 of the amino acid sequence set forth as SEQ ID NO:
- 2, or an antigen binding fragment of the monoclonal antibody, and wherein the monoclonal antibody specifically binds an epitope of insulin like growth factor (IGF)-II.
(canceled)
(canceled)
An engineered antibody domain, comprising a heavy chain complementarity determining region (H-CDR)1, an H-CDR2 and H-CDR3, wherein the H-CDR1 comprises the amino acid sequence set forth as amino acids 26 to 33 of the amino acid sequence set forth as SEQ ID NO:
- 5, the H-CDR2 comprises amino acids 51 to 58 of the amino acid sequence set forth as SEQ ID NO:
- 5, and the H-CDR3 comprises amino acids 97 to 117 of the amino acid sequence set forth as SEQ ID NO:
- 5, wherein the engineered antibody domain specifically binds an epitope of insulin like growth factor-II.
35-37. (canceled)
Dependencies are inferred from the claim text.